Nonalcoholic fatty liver disease and the coronary artery disease

Sombat Treeprasertsuk, Francisco Lopez-Jimenez, Keith D. Lindor

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and is recognized as part of the metabolic syndrome (MetS). Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death. Aims: We aim to address the epidemiological data of CAD, the possible pathogenesis or linkage mechanisms of NAFLD and atherosclerosis and the strategies to reduce the CAD risk in NAFLD patients. Methods: We reviewed data from a Medline and PubMed search which was performed to identify relevant literature using search terms "NAFLD," "metabolic syndrome" and "coronary artery disease." Results: Patients with steatohepatitis, a part of the spectrum of NAFLD, have more cardiovascular events than patients without steatohepatitis. However, the association between liver histological progression and the risk of CAD events is not linear. A multidisciplinary approach to NAFLD patients based on controlling related risk factors and monitoring for CAD risks and liver complications is necessary. The combination of lifestyle modification with pharmacological treatment tailored to each individual's risk factors needs to be considered. There is a need for more research on primary prevention for CAD in NAFLD patients and interventional studies for determining the nature of the relationship between NAFLD and CAD. Conclusions: NAFLD is recognized as part of the MetS and increases cardiovascular risks. Therefore, a multidisciplinary approach to these patients of controlling the related risk factors and monitoring for cardiovascular and liver complications must be done.

Original languageEnglish (US)
Pages (from-to)35-45
Number of pages11
JournalDigestive Diseases and Sciences
Volume56
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Coronary Artery Disease
Fatty Liver
Liver
Metabolic Syndrome X
Non-alcoholic Fatty Liver Disease
Primary Prevention
Life Expectancy
PubMed
Life Style
Cause of Death
Atherosclerosis
Pharmacology
Research
Population

Keywords

  • Coronary artery disease
  • Management
  • Nonalcoholic fatty liver disease

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Nonalcoholic fatty liver disease and the coronary artery disease. / Treeprasertsuk, Sombat; Lopez-Jimenez, Francisco; Lindor, Keith D.

In: Digestive Diseases and Sciences, Vol. 56, No. 1, 01.2011, p. 35-45.

Research output: Contribution to journalArticle

Treeprasertsuk, Sombat ; Lopez-Jimenez, Francisco ; Lindor, Keith D. / Nonalcoholic fatty liver disease and the coronary artery disease. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 1. pp. 35-45.
@article{5329525551e44d7a8f26d5f05551fd24,
title = "Nonalcoholic fatty liver disease and the coronary artery disease",
abstract = "Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and is recognized as part of the metabolic syndrome (MetS). Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death. Aims: We aim to address the epidemiological data of CAD, the possible pathogenesis or linkage mechanisms of NAFLD and atherosclerosis and the strategies to reduce the CAD risk in NAFLD patients. Methods: We reviewed data from a Medline and PubMed search which was performed to identify relevant literature using search terms {"}NAFLD,{"} {"}metabolic syndrome{"} and {"}coronary artery disease.{"} Results: Patients with steatohepatitis, a part of the spectrum of NAFLD, have more cardiovascular events than patients without steatohepatitis. However, the association between liver histological progression and the risk of CAD events is not linear. A multidisciplinary approach to NAFLD patients based on controlling related risk factors and monitoring for CAD risks and liver complications is necessary. The combination of lifestyle modification with pharmacological treatment tailored to each individual's risk factors needs to be considered. There is a need for more research on primary prevention for CAD in NAFLD patients and interventional studies for determining the nature of the relationship between NAFLD and CAD. Conclusions: NAFLD is recognized as part of the MetS and increases cardiovascular risks. Therefore, a multidisciplinary approach to these patients of controlling the related risk factors and monitoring for cardiovascular and liver complications must be done.",
keywords = "Coronary artery disease, Management, Nonalcoholic fatty liver disease",
author = "Sombat Treeprasertsuk and Francisco Lopez-Jimenez and Lindor, {Keith D.}",
year = "2011",
month = "1",
doi = "10.1007/s10620-010-1241-2",
language = "English (US)",
volume = "56",
pages = "35--45",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease and the coronary artery disease

AU - Treeprasertsuk, Sombat

AU - Lopez-Jimenez, Francisco

AU - Lindor, Keith D.

PY - 2011/1

Y1 - 2011/1

N2 - Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and is recognized as part of the metabolic syndrome (MetS). Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death. Aims: We aim to address the epidemiological data of CAD, the possible pathogenesis or linkage mechanisms of NAFLD and atherosclerosis and the strategies to reduce the CAD risk in NAFLD patients. Methods: We reviewed data from a Medline and PubMed search which was performed to identify relevant literature using search terms "NAFLD," "metabolic syndrome" and "coronary artery disease." Results: Patients with steatohepatitis, a part of the spectrum of NAFLD, have more cardiovascular events than patients without steatohepatitis. However, the association between liver histological progression and the risk of CAD events is not linear. A multidisciplinary approach to NAFLD patients based on controlling related risk factors and monitoring for CAD risks and liver complications is necessary. The combination of lifestyle modification with pharmacological treatment tailored to each individual's risk factors needs to be considered. There is a need for more research on primary prevention for CAD in NAFLD patients and interventional studies for determining the nature of the relationship between NAFLD and CAD. Conclusions: NAFLD is recognized as part of the MetS and increases cardiovascular risks. Therefore, a multidisciplinary approach to these patients of controlling the related risk factors and monitoring for cardiovascular and liver complications must be done.

AB - Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and is recognized as part of the metabolic syndrome (MetS). Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death. Aims: We aim to address the epidemiological data of CAD, the possible pathogenesis or linkage mechanisms of NAFLD and atherosclerosis and the strategies to reduce the CAD risk in NAFLD patients. Methods: We reviewed data from a Medline and PubMed search which was performed to identify relevant literature using search terms "NAFLD," "metabolic syndrome" and "coronary artery disease." Results: Patients with steatohepatitis, a part of the spectrum of NAFLD, have more cardiovascular events than patients without steatohepatitis. However, the association between liver histological progression and the risk of CAD events is not linear. A multidisciplinary approach to NAFLD patients based on controlling related risk factors and monitoring for CAD risks and liver complications is necessary. The combination of lifestyle modification with pharmacological treatment tailored to each individual's risk factors needs to be considered. There is a need for more research on primary prevention for CAD in NAFLD patients and interventional studies for determining the nature of the relationship between NAFLD and CAD. Conclusions: NAFLD is recognized as part of the MetS and increases cardiovascular risks. Therefore, a multidisciplinary approach to these patients of controlling the related risk factors and monitoring for cardiovascular and liver complications must be done.

KW - Coronary artery disease

KW - Management

KW - Nonalcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=79151478841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151478841&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1241-2

DO - 10.1007/s10620-010-1241-2

M3 - Article

C2 - 20464495

AN - SCOPUS:79151478841

VL - 56

SP - 35

EP - 45

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 1

ER -